Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Praxis|October 31, 2013
[Hoarsness after a trip to the United States of America]Aleksandra Nobile, Reto A Schüpbach, Markus Flepp, et al.BMJ Open|May 19, 2021
Assessing relative COVID-19 mortality: a Swiss population-based studyTorsten Hothorn, Matthias Bopp, Huldrych Günthard, et al.BMJ Open|October 5, 2021
Assessing relative COVID-19 mortality during the second wave: a prospective Swiss population-based studySandra Siegfried, Matthias Bopp, Huldrych Günthard, et al.AIDS (London, England)|July 11, 2017
Adverse events of raltegravir and dolutegravirLuigia Elzi, Stefan Erb, Hansjakob Furrer, et al.AIDS (London, England)|March 8, 2005
Biphasic decline of CD4 cell count during scheduled treatment interruptionsCatherine Fagard, Cédric Y Bandelier, Jintanat Ananworanich, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 3, 2025
Late Re-Engagement Into HIV Care Among Adults in the Swiss HIV Cohort StudyAndreas D Haas, Katharina Kusejko, Matthias Cavassini, et al.AIDS (London, England)|December 20, 2007
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort StudyMarcel Wolbers, Milos Opravil, Viktor von Wyl, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2005
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell lossJörg Schüpbach, Huldrych Günthard, Beda Joos, et al.AIDS (London, England)|June 26, 2003
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAARTCatherine Fagard, Michelle Le Braz, Huldrych Günthard, et al.Virology|March 10, 2009
Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activitySteven Yukl, Satish Pillai, Peilin Li, et al.Pageof 2